A 62-year-old woman received RBX2660, an investigational microbiome restoration therapeutic, for recurrent multidrug-resistant (MDR) urinary tract infection (UTI). RBX2660 increased gut microbiome diversity but did not eliminate uropathogen carriage, and MDR UTI recurred after subsequent antibiotic exposure. Thus, restoration of microbiome diversity does not preclude disease recurrence by residual MDR pathogens.
Keywords: antibiotic resistance; fecal microbiota transplant; microbial restoration therapy; microbiome; urinary tract infection.
© The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America.